used a phage display screening ... with CAR T cell therapy represents a promising avenue for clinical advancement. The PD-1-PD-L1 axis, which impedes CAR-T cell efficiency, could be blocked through ...

Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy. Oncolytic virus therapies utilize genetically modified or ...

Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...

Thibaut du Fayet, Chief Executive Officer of PHAXIAM, stated: “We start 2025 with a clear ambition to position PHAXIAM as a Specialty Pharma in Critical care, in the booming phage therapy market.

Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' trials predating Fleming's discovery of penicillin by approximately a decade. In this ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...